Monoclonal antibody isolation and characterization for COVID-19 Effort

COVID-19 的单克隆抗体分离和表征

• 批准号: 10497767
• 负责人: Rosemarie Mason
• 金额: $ 42.84万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10497767
• 关键词: 2019-nCoV; Antibodies; Antibody Therapy; Antigens; Biological Assay; COVID-19; COVID-19 vaccination; Cells; Development; Evaluation; Generations; Human; In Vitro; Monoclonal Antibodies; Prevention; Reproducibility; SARS-CoV-2 antibody; SARS-CoV-2 infection; Sampling; Serum; Virus Diseases; base; interest; stable cell line; vaccine development; variants of concern

To date, we have isolated more than 100 SARS-CoV-2-specific monoclonal antibodies (mAbs) from SARS-CoV-2 convalescent donors and characterized their functionality in vitro. More than 25 of these mAbs isolated and characterized were neutralizing against SARS-CoV-2 with several also able to neutralize multiple Variants of Concern (VOC). Two of these antibodies are of particular interest: one for its ability to potently neutralize SARS-CoV-2 and multiple VOCs and another for its ability to neutralize SARS-CoV-2, multiple VOCs as well as SARS1. We are also isolating and characterizing mAbs from cells of human donors who have been fully vaccinated against SARS-CoV-2 as well as donors who have been infected with VOC. We are also working on generation of a stable cell line co-expressing hACE2 and TMPRSS2a for use as target cells in the SARS-CoV-2 pseudovirus neutralization assay. Once established, this stable cell line will allow for consistent and reproducible evaluation of neutralizing activity by mAb and human donor serum samples in vitro.

到目前为止，我们已经从SARS-CoV-2恢复期供体中分离出了100多个SARS-CoV-2特异性单克隆抗体（mAb），并在体外表征了它们的功能。这些分离和表征的mAb中有超过25种能够中和SARS-CoV-2，其中几种还能够中和多种关注变体（VOC）。其中两种抗体特别令人感兴趣：一种是能够有效地中和SARS-CoV-2和多种VOC，另一种是能够中和SARS-CoV-2、多种VOC以及SARS 1。我们还从已完全接种SARS-CoV-2疫苗的人类供体以及已感染VOC的供体的细胞中分离和表征mAb。 我们还在研究共表达hACE 2和TMPRSS 2a的稳定细胞系的产生，以用作SARS-CoV-2假病毒中和试验中的靶细胞。一旦建立，该稳定的细胞系将允许在体外对mAb和人供体血清样品的中和活性进行一致和可重现的评价。